Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.7700 (-0.76%) ($11.7450 - $11.7700) on Fri. Jan. 6, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.79% (three month average) | RSI | 44 | Latest Price | $11.7700(-0.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(52%) IWM(42%) IWO(42%) IWC(41%) IWN(40%) | Factors Impacting FOLD price | FOLD will decline at least -1.395% in a week (0% probabilities). XLU(-12%) VXX(-12%) VIXM(-12%) ARKG(-12%) VCIT(-9%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.395% (StdDev 2.79%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.95 | 5 Day Moving Average | $11.95(-1.51%) | 10 Day Moving Average | $11.87(-0.84%) | 20 Day Moving Average | $11.95(-1.51%) | To recent high | -7.4% | To recent low | 17.7% | Market Cap | $3.039b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |